Skip to main content
Midas Edge

Gossamer Bio Inc

For the period ended Sep 30, 2024. Filed Nov 7, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 7, 2024

GOSS$11.28+6.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

(in thousands, except share amounts)

Common stock · Additional paid-in capital · Accumulated deficit · Accumulated other comprehensive loss · Total stockholders' equity
Shares · Amount
Balance as of December 31, 2023225,409,315$23$1,275,136$(1,212,040)$(350)$62,769
Stock-based compensation——5,811——5,811
Issuance of common stock pursuant to Employee Stock Purchase Plan390,246—348——348
Issuance of common stock for restricted stock units vested419,092—————
Net loss———(41,928)—(41,928)
Other comprehensive loss————(278)(278)
Balance as of March 31, 2024226,218,653$23$1,281,295$(1,253,968)$(628)$26,722
Stock-based compensation——5,001——5,001
Issuance of common stock for restricted stock units vested8,606—————
Grant of equity option pursuant to Chiesi Collaboration Agreement——464——464
Net income———49,232—49,232
Other comprehensive income————110110
Balance as of June 30, 2024226,227,259$23$1,286,760$(1,204,736)$(518)$81,529
Stock-based compensation——4,842——4,842
Issuance of common stock pursuant to Employee Stock Purchase Plan376,879—281——281
Net loss———(30,803)—(30,803)
Other comprehensive loss————(1,713)(1,713)
Balance as of September 30, 2024226,604,138$23$1,291,883$(1,235,539)$(2,231)$54,136
Common stock · Additional paid-in capital · Accumulated deficit · Accumulated other comprehensive loss · Total stockholders' equity (deficit)
Shares · Amount
Balance as of December 31, 202294,423,181$10$1,044,864$(1,032,223)$(574)$12,077
Vesting of restricted stock55,225—————
Stock-based compensation——8,127——8,127
Issuance of common stock pursuant to Employee Stock Purchase Plan249,623—367——367
Issuance of common stock for restricted stock units vested716,067—————
Net loss———(49,165)—(49,165)
Other comprehensive income————138138
Balance as of March 31, 202395,444,096$10$1,053,358$(1,081,388)$(436)$(28,456)
Stock-based compensation——8,197——8,197
Issuance of common stock for restricted stock units vested8,607—————
Net loss———(42,496)—(42,496)
Other comprehensive loss————(45)(45)
Balance as of June 30, 202395,452,703$10$1,061,555$(1,123,884)$(481)$(62,800)
Issuance of common stock in connection with a private offering, net of offering costs of $10,779129,869,44013201,310——201,323
Stock-based compensation——6,162——6,162
Issuance of common stock pursuant to Employee Stock Purchase Plan87,172—77——77
Net loss———(40,008)—(40,008)
Other comprehensive loss————(137)(137)
Balance as of September 30, 2023225,409,315$23$1,269,104$(1,163,892)$(618)$104,617
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.